MedTrace Logo

Study Regarding the Incidence of Anti-platelet Factor 4-antibodies in Patients Aged 18 to 60 Years With Spontaneous or Infection- or Vaccine-associated or Recurrent Venous and/or Arterial Thrombosis

NCT06650826 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2024-10-21

No results posted yet for this study

Summary

Prospective investigation of the incidence of anti-platelet factor 4 antibodies in suspected immune-associated arterial and/or venous thrombosis

Conditions

  • Arterial or Venous Thrombosis

Interventions

DIAGNOSTIC_TEST

Determination of anti-platelet factor 4 antibodies in the blood

The anti-platelet factor 4 antibodies in the blood are determined using latex agglutination and the chemiluminescence method in the coagulation laboratory of the CCB MVZ laboratory. In addition, the platelet factor 4-induced platelet activation test (PIPA test) and the heparin-induced platelet activation test (HIPA test) as well as an ELISA-based platelet factor 4 IgG antibody test (Prof. Greinacher, Greifswald University Hospital) will be performed as part of the routine work up. In addition a new assay for heparin-independent anti-PF4 antibody detection provided by the company Werfen using chemiluminescence will be performed.

Sponsors & Collaborators

  • Cardioangiologisches Centrum Bethanien

    lead OTHER

Principal Investigators

  • Edelgard Lindhoff-Last, Professor · Cardioangiologisches Zentrum Bethanien

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-01
Primary Completion
2026-07-31
Completion
2027-01-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06650826 on ClinicalTrials.gov